162
Participants
Start Date
August 31, 2015
Primary Completion Date
December 8, 2020
Study Completion Date
December 8, 2020
HM61713
"800 mg QD continuously in 21-day cycles until disease progression determined by investigator assessment per RECIST version 1.1, and as long as, in the investigators opinion, they are benefiting from study treatment and they do not meet any of treatment discontinuation criteria."
Research Site, Beverly Hills
Research Site, Burbank
Research Site 2, Los Angeles
Research Site, Los Angeles
Research Site, Montebello
Research Site, Orange
Research Site, San Diego
Research Site, Boca Raton
Research Site, Honolulu
Research Site, Evanston
Research Site, Bethesda
Research Site, Boston
Research Site, Lebanon
Research Site, Charlotte
Research Site, Washington
Research Site, Darlinghurst
Research site, Fitzroy
Research Site, Frankston
Research Site, Kogarah
Research Site, St Albans
Research Site, Woolloongabba
Research Site, Toronto
Research Site, Berlin
Research Site, Homburg
Research Site, Leipzig
Research Site, München
Research Site, Ulm
Research Site, Bergamo
Research Site, Bologna
Research Site, Catania
Research Site, Milan
Research Site, Rome
Research Site, George Town
Research Site, Kuala Lumpur
Research Site, Kuantan
Research Site, Kuching
Research Site, Makati
Research Site, Pasig
Research Site 2, Manila
Research Site, Manila
Research Site, Cebu
Research Site, Cheongju-si
Research Site, Goyang-si
Research Site, Hwasun
Research Site, Incheon
Research Site 2, Seongnam-si
Research Site, Seongnam-si
Research Site 2, Seoul
Research Site 3, Seoul
Research Site 4, Seoul
Research Site 5, Seoul
Research Site 6, Seoul
Research Site 7, Seoul
Research Site 8, Seoul
Research Site, Seoul
Research Site, A Coruña
Research Site 2, Barcelona
Research Site 3, Barcelona
Research Site 4, Barcelona
Research Site, Barcelona
Research Site, Donostia / San Sebastian
Research Site 2, Madrid
Research Site, Madrid
Research Site, Navarra
Research Site 2, Valencia
Research Site, Valencia
Research Site, Kaohsiung City
Research Site, Taichung
Research Site 2, Tainan City
Research Site, Tainan City
Research Site 2, Taipei
Research Site, Taipei
Lead Sponsor
Hanmi Pharmaceutical Company Limited
INDUSTRY